- Home
- MOGO vs BCAB Comparison
MOGO vs BCAB Comparison
Compare MOGO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOGO | BCAB |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MOGO | BCAB |
|---|---|---|
| Price | $1.19 | $0.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $4.00 | $1.00 |
| AVG Volume (30 Days) | 109.5K | ★ 2.1M |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $29,215,516.00 | N/A |
| Revenue This Year | $63.05 | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $5.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $0.24 |
| 52 Week High | $3.83 | $1.53 |
Technical Indicators
Market Signals| Indicator | MOGO | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 51.71 |
| Support Level | $1.14 | $0.79 |
| Resistance Level | $1.22 | $0.90 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 21.05 | 41.16 |
Price Performance
Historical ComparisonAbout MOGO Mogo Inc.
Mogo Inc is a Canadian-based financial technology company. It offers a finance application to consumers with solutions that help them to control their financial health. At Mogo, users can sign up for a free account and get access to products and solutions that help users to monitor their credit score, protect themselves from identity fraud, control their spending, and borrow responsibly. Company offers digital loans and mortgages and also offer a digital payments platform that powers next-generation card programs for both established world-wide corporations and fintech companies in Europe and Canada.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.